Kyle Kuvalanka
Director/Board Member presso IMV INC.
Patrimonio netto: - $ in data 31/12/2023
Profilo
Kyle D.
Kuvalanka is an Independent Director at IMV, Inc. and will be the Chief Financial Officer & Chief Business Officer at Rome Therapeutics, Inc. starting in 2023.
He was previously the Vice President-Strategy & Business Development at Millennium Pharmaceuticals, Inc. from 2009 to 2013, the CFO, Treasurer, CAO & Chief Business Officer at Blueprint Medicines Corp.
from 2013 to 2015, and the Chief Operating, Financial & Accounting Officer at Syros Pharmaceuticals, Inc. from 2015 to 2017.
He also held the position of Chief Operating & Financial Officer at Goldfinch Bio, Inc. Mr. Kuvalanka received his undergraduate degree from Wesleyan University and his MBA from The Wharton School of the University of Pennsylvania.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
IMV INC.
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 31/12/2023 |
Posizioni attive di Kyle Kuvalanka
| Società | Posizione | Inizio |
|---|---|---|
| IMV INC. | Director/Board Member | 01/04/2021 |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | Director of Finance/CFO | 04/10/2023 |
Precedenti posizioni note di Kyle Kuvalanka
| Società | Posizione | Fine |
|---|---|---|
| SYROS PHARMACEUTICALS, INC. | Director of Finance/CFO | 22/09/2017 |
| BLUEPRINT MEDICINES CORPORATION | Director of Finance/CFO | 18/09/2015 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/09/2013 |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Director of Finance/CFO | - |
Formazione di Kyle Kuvalanka
| Wesleyan University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| IMV INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| SYROS PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Health Technology |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Kyle Kuvalanka
